Aberrant Sleep Patterns Show Risk Associated With Status Migrainosus Recurrence
June 11th 2022Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.
Eculizumab Shows Better Prolonging of Time to NMOSD Relapse Than Other Treatments
October 17th 2021An indirect comparison study evaluated relative treatment effects of eculizumab (Soliris; Alexion), inebilizumab (Uplizna; Horizon), and satralizumab (Enspryng; Genentech), the 3 FDA-approved options for NMOSD.
Cutting Edge Care in Multiple Sclerosis: Advances in S1P Therapy
July 28th 2021Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).
Mayo Clinic: Institutional Perspectives in Neurology, Chaired by Brian G. Weinshenker, MD
July 16th 2021Chaired by Brian G. Weinshenker, MD, the presentations also feature Mayo Clinic experts W. Oliver Tobin, MBBCh, BAO, PhD; Jessica Stulc, MD, MPH; and Orhun H. Kantarci, MD. [WATCH TIME: 1 hour, 30 minutes]